Overview
Showing Patients with Migraine the Possibilities with CGRP mAbs
Migraine Expert Perspectives
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This activity focuses on the latest data with calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) as well as personalized migraine treatment. Leading migraine experts, Jessica Ailani, MD, FAHS, FAAN and Richard Wenzel, PharmD discuss factors that influence treatment, strategies to improve therapeutic adherence, and comprehensive care strategies. To accompany this education, a short, patient-centered animated whiteboard is also provided to help frame foundational knowledge about the CGRP mAbs.
This activity is intended for neurologists, headache specialists, and pharmacists who manage patients with migraine. The whiteboard is designed for patients with migraine.
Migraine is ranked as the third most prevalent disorder and seventh-highest specific cause of disability worldwide, accounting for 30% of the global burden of disease and 50% of the world’s neurological disease-related disability. Migraine is such a common disorder that it is more prevalent than diabetes, epilepsy, and asthma combined. Current employment-related costs due to migraine-related lost productivity are estimated at more than $14 billion annually. Problematically, a 2016 study found that less than 5% of patients with chronic migraine received appropriate care, likely due to poor treatment adherence over the long term.
Secondary to the significance of migraine coupled with the ongoing care gaps, healthcare providers need to be better prepared to develop effective treatment plans for patients with episodic and chronic migraine. Healthcare providers also need to improve their shared decision-making with their patients with migraine to ensure that patients’ goals and desires are incorporated into therapy selection. Upon completing this activity, healthcare providers will be better able to create appropriate, patient-centered episodic and chronic migraine treatment regimens.
Upon completion of this activity, healthcare professionals will be able to:
• Evaluate and discuss the efficacy, safety and tolerability of CGRP mAbs for the treatment of acute and chronic migraine
• Develop effective strategies for improving patient adherence to therapies
• Employ clinical shared decision-making strategies to address patient fears and promote optimal self-management
• Evaluate and discuss the efficacy, safety and tolerability of CGRP mAbs for the treatment of acute and chronic migraine
• Develop effective strategies for improving patient adherence to therapies
• Employ clinical shared decision-making strategies to address patient fears and promote optimal self-management
Upon completion of this activity, pharmacists will be able to:
• Interpret and discuss the efficacy, safety and tolerability of CGRP mAbs for the treatment of acute and chronic migraine
• Apply effective strategies for improving patient adherence to therapies
• Employ clinical shared decision-making strategies to address patient fears and promote optimal self-management
Topic #1: Factors that influence treatment selection and adherence
Topic #2: The promise of CGRP mAbs in migraine prevention
Topic #3: Comprehensive care strategies
Topic #4: Enhancing shared decision-making in migraine care
Topic #2: The promise of CGRP mAbs in migraine prevention
Topic #3: Comprehensive care strategies
Topic #4: Enhancing shared decision-making in migraine care
Supported by an educational grant from Lundbeck.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 10.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Jessica Ailani, MD, FAHS, FAAN
Director, MedStar Georgetown Headache Center
McLean, VA
Director, MedStar Georgetown Headache Center
McLean, VA
Richard Wenzel, PharmD, CPPS
Consultant Pharmacist
Chicago Headache Center
Chicago, IL
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Jessica Ailani, MD, FAHS, FAAN
Sources of Funding for Research: Abbvie, Biohaven, Eli Lilly, Impel, Lundbeck, Satsuma, Zosano,
Consulting Agreements: Abbvie, Amgen, Aeon, BioDeliveryScience, Biohaven, Glaxo Smith Kline, Eli Lilly, Miravo, Nesos, Satsuma, Teva
Advisory Board: BioDeliveryScience, Impel, Lundbeck, Teva
Richard Wenzel, PharmD, CPPS
Employee: Eli Lilly & Company (2018- January 2022)
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
CPE credit will be submitted to CPE Monitor® on the first business day of each month.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity has been approved for 1.0 contact hours.
ACPE Universal Activity Number: 0396-0000-22-058-H01-P
Activity Type(s): Application
